ARRIVENT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.1 USD | -0.25% |
|
+13.56% | 0.00% |
| 16/05 | ArriVent BioPharma, Inc. Appoints John Hohneker as Board of Directors | CI |
| 08/05 | ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 673.2 | - | - |
| Enterprise Value (EV) 1 | 472.5 | 171.4 | 281 |
| P/E ratio | -6.88 x | -6.78 x | -6.51 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 52.2 x |
| EV / Revenue | - | - | 21.8 x |
| EV / EBITDA | -5.3 x | -1.52 x | -2.09 x |
| EV / FCF | -7.92 x | -2.5 x | -3.57 x |
| FCF Yield | -12.6% | -40% | -28% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 33,494 | - | - |
| Reference price 2 | 20.10 | 20.10 | 20.10 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 12.9 |
| EBITDA 1 | - | - | -89.23 | -113 | -134.3 |
| EBIT 1 | - | -74.59 | -109.3 | -104.2 | -110.7 |
| Operating Margin | - | - | - | - | -858.42% |
| Earnings before Tax (EBT) 1 | - | -69.33 | -78.21 | -92.18 | -101.4 |
| Net income 1 | -36.91 | -69.33 | -78.21 | -92.18 | -101.4 |
| Net margin | - | - | - | - | -786.29% |
| EPS 2 | -1.900 | -32.38 | -2.922 | -2.963 | -3.086 |
| Free Cash Flow 1 | - | -61.1 | -59.7 | -68.5 | -78.6 |
| FCF margin | - | - | - | - | -609.3% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 25/08/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -20.67 | -21.58 | -22.52 | -24.45 | - | - |
| EBIT 1 | -20.67 | -23.55 | -37.72 | -27.32 | -24.47 | -25.13 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -17.42 | -19 | -20.12 | -21.67 | -21.23 | -22.14 |
| Net income 1 | -17.42 | -19 | -20.12 | -21.67 | -21.23 | -22.14 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.7000 | -0.5667 | -0.5978 | -0.6435 | -0.6300 | -0.6500 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 08/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 150 | 201 | 502 | 392 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -61.1 | -59.7 | -68.5 | -78.6 |
| ROE (net income / shareholders' equity) | - | - | -15.8% | -3.94% | -3.99% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | - | - | 1 |
| Capex / Sales | - | - | - | - | 7.75% |
| Announcement Date | 25/08/23 | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.1
USD
Average target price
30.2
USD
Spread / Average Target
+50.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 673M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- AVBP Stock
- Financials ArriVent BioPharma, Inc.
